Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 196 JPY 0.51% Market Closed
Market Cap: 17.7B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Healios KK
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Other Operating Expenses
ÂĄ57m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Other Operating Expenses
ÂĄ9.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Other Operating Expenses
-ÂĄ52.4m
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Other Operating Expenses
-ÂĄ206m
CAGR 3-Years
45%
CAGR 5-Years
19%
CAGR 10-Years
-59%
Pharma Foods International Co Ltd
TSE:2929
Other Operating Expenses
-ÂĄ1m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
17.7B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.89 JPY
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Healios KK's Other Operating Expenses?
Other Operating Expenses
57m JPY

Based on the financial report for Sep 30, 2024, Healios KK's Other Operating Expenses amounts to 57m JPY.

What is Healios KK's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 1Y
375%

Over the last year, the Other Operating Expenses growth was 375%.

Back to Top